TED01RV: A multicenter, double-masked, placebo-controlled, efficacy and safety study of rv 001, an insulin-like growth factor-1 receptor (igf-1r) antagonist antibody (fully human), administered every 3 weeks (q3w) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (ted)
Laufzeit: 01.01.2013 - 31.12.2017